Biotechnology and Health Sciences Biotechnology and Health Sciences Biotech Health Sci http://www.Biotech-health.portal.tools 2383-0271 2383-028X 10.5812/bhs en jalali 2019 11 12 gregorian 2019 11 12 2 2
en 10.17795/bhs-27547 Bee Venom Induces Unfolded Protein Response in A172 Glioblastoma Cell Line Bee Venom Induces Unfolded Protein Response in A172 Glioblastoma Cell Line brief-report brief-report Background

Glioblastoma is a type of brain tumor with poor response to available therapies, and shows high rate of mortality. Despite remarkable advancements in our knowledge about cytogenetic and pathophysiologic features of glioblastoma, current treatment strategies are mainly based on cytotoxic drugs; however, these therapeutic approaches are facing progressive failure because of the resistant nature of glioblastomas. In the recent years, however, promising results have emerged owing to targeted therapies toward molecular pathways within cancerous cells. Unfolded Protein Response (UPR) is a remarkable signaling pathway that triggers both apoptosis and survival pathways within cells, and therefore induces UPR-related apoptotic pathways in cancer cells by ER stress inducers.

Objectives

Recently, the role of Bee venom (Bv), which contains powerful bioactive peptides, in inducing UPR-related apoptosis was revealed in cancer cell lines. Nevertheless, currently there are no reports of Bv potential ability in induction of UPR apoptotic routes in glioblastoma. The aim of current study was to evaluate possible role of Bee venome in inducing of UPR pathway within A172 glioblastoma cell line.

Materials and Methods

We treated the A172 glioblastoma cell line with different Bv doses, and assessed UPR-related genes expression by real-time Polymerase Chain Reaction (PCR).

Results

The IC50 of Bv for the studied cell line was 28 μg/mL. Furthermore, we observed that Bv can induce UPR target genes (Grp94 and Gadd153) over-expression through a dose-dependent mechanism.

Conclusions

Our results suggest the potential role of Bv as a therapeutic agent for glioblastomas.

Background

Glioblastoma is a type of brain tumor with poor response to available therapies, and shows high rate of mortality. Despite remarkable advancements in our knowledge about cytogenetic and pathophysiologic features of glioblastoma, current treatment strategies are mainly based on cytotoxic drugs; however, these therapeutic approaches are facing progressive failure because of the resistant nature of glioblastomas. In the recent years, however, promising results have emerged owing to targeted therapies toward molecular pathways within cancerous cells. Unfolded Protein Response (UPR) is a remarkable signaling pathway that triggers both apoptosis and survival pathways within cells, and therefore induces UPR-related apoptotic pathways in cancer cells by ER stress inducers.

Objectives

Recently, the role of Bee venom (Bv), which contains powerful bioactive peptides, in inducing UPR-related apoptosis was revealed in cancer cell lines. Nevertheless, currently there are no reports of Bv potential ability in induction of UPR apoptotic routes in glioblastoma. The aim of current study was to evaluate possible role of Bee venome in inducing of UPR pathway within A172 glioblastoma cell line.

Materials and Methods

We treated the A172 glioblastoma cell line with different Bv doses, and assessed UPR-related genes expression by real-time Polymerase Chain Reaction (PCR).

Results

The IC50 of Bv for the studied cell line was 28 μg/mL. Furthermore, we observed that Bv can induce UPR target genes (Grp94 and Gadd153) over-expression through a dose-dependent mechanism.

Conclusions

Our results suggest the potential role of Bv as a therapeutic agent for glioblastomas.

Glioblastoma;A172 Cell Line;Unfolded Protein Response;Bee Venom Glioblastoma;A172 Cell Line;Unfolded Protein Response;Bee Venom http://www.Biotech-health.portal.tools/index.php?page=article&article_id=27547 Ali Bazi Ali Bazi Cancer Molecular Pathology Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran; Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, IR Iran; Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, IR Iran. Tel/Fax: +98-5432232166 Cancer Molecular Pathology Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran; Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, IR Iran; Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, IR Iran. Tel/Fax: +98-5432232166 Mehran Gholamin Mehran Gholamin Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, IR Iran Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, IR Iran Mohsen Sisakht Mohsen Sisakht Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran Mohammad Reza Keramati Mohammad Reza Keramati Cancer Molecular Pathology Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran Cancer Molecular Pathology Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran